electroCore (NASDAQ:ECOR) Issues Quarterly Earnings Results

Posted by Geri Gentry on Aug 7th, 2026

electroCore (NASDAQ:ECOR – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.09, FiscalAI reports. electroCore had a negative net margin of 39.96% and a negative return on equity of 1,956.38%. The company had revenue of $9.45 million for the quarter, compared to analyst estimates of $9.49 million.

Here are the key takeaways from electroCore’s conference call:

Revenue grew 28% year over year to $9.5 million, driven by VA prescription sales of gammaCore and Quell, along with Truvaga growth. Management raised 2026 revenue guidance to more than 30% growth.
Operating performance improved, with GAAP net loss narrowing to $3.1 million and adjusted EBITDA loss improving 26% year over year to $1.8 million. Management believes the commercial restructuring creates a path to positive adjusted EBITDA in the third quarter of 2027 without a dilutive equity raise.
Quell was a major growth driver, with second-quarter sales up approximately 700% year over year to $1.3 million. The company is expanding Quell utilization across existing VA accounts and is targeting an FDA submission by year-end for chemotherapy-induced peripheral neuropathy.
electroCore doubled its sales regions, added 17 independent representatives covering 29 VA medical centers, and is expanding into the Department of Defense, federal workers’ compensation, first responders, and other federal channels. Moving federal supply schedule sales to Lovell Government Services is expected to reduce related costs by roughly 3% of general and administrative expenses and transaction fees.
Truvaga faced rising competition and advertising costs, with direct cost per click increasing roughly 30% and media efficiency declining. In addition, FDA observations regarding patient-complaint processes will delay a potential Quell 2.0 rebrand and direct-to-consumer relaunch, while VA account concentration remains a risk after a facility staffing issue shifted approximately $145,000 of revenue into the third quarter.

electroCore Trading Up 20.7%

NASDAQ ECOR traded up $1.39 on Friday, reaching $8.09. The company’s stock had a trading volume of 213,989 shares, compared to its average volume of 67,392. The firm has a market cap of $72.97 million, a PE ratio of -4.87 and a beta of 0.92. The business has a 50-day moving average price of $7.69 and a 200 day moving average price of $6.99. electroCore has a 52 week low of $4.16 and a 52 week high of $10.49.

Insider Activity

In other electroCore news, Director Thomas J. Errico purchased 9,992 shares of the business’s stock in a transaction on Thursday, May 21st. The stock was purchased at an average price of $5.99 per share, for a total transaction of $59,852.08. Following the completion of the purchase, the director directly owned 360,071 shares in the company, valued at approximately $2,156,825.29. This trade represents a 2.85% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Joshua S. Lev sold 6,667 shares of electroCore stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $9.00, for a total value of $60,003.00. Following the sale, the chief financial officer directly owned 84,889 shares in the company, valued at $764,001. The trade was a 7.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 7.80% of the company’s stock.

Institutional Trading of electroCore

Several institutional investors have recently bought and sold shares of ECOR. Two Sigma Investments LP grew its position in electroCore by 20.8% in the third quarter. Two Sigma Investments LP now owns 24,603 shares of the company’s stock valued at $122,000 after acquiring an additional 4,231 shares during the period. Jane Street Group LLC lifted its holdings in shares of electroCore by 114.4% during the first quarter. Jane Street Group LLC now owns 36,726 shares of the company’s stock valued at $246,000 after acquiring an additional 19,599 shares during the period. Cubist Systematic Strategies LLC bought a new position in shares of electroCore during the first quarter valued at $153,000. DRW Securities LLC acquired a new stake in shares of electroCore in the 4th quarter valued at $264,000. Finally, NewEdge Advisors LLC boosted its stake in shares of electroCore by 857.9% in the 1st quarter. NewEdge Advisors LLC now owns 161,955 shares of the company’s stock valued at $1,083,000 after purchasing an additional 145,047 shares in the last quarter. Institutional investors and hedge funds own 26.74% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of electroCore in a report on Wednesday, June 24th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $18.00.

Read Our Latest Stock Report on ECOR

About electroCore

(Get Free Report)

electroCore, Inc is a commercial-stage bioelectronic medicine company headquartered in Rockaway, New Jersey. The company specializes in the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies designed to address a variety of neurological and inflammatory conditions. Established in 2006, electroCore has focused its efforts on translating neuromodulation science into a compact, patient-administered treatment device.

The company’s lead product, gammaCore®, is a handheld, battery-powered device that delivers nVNS through the skin to the cervical branch of the vagus nerve.